Tiny Stem Cell Companies Close in on Major Heart Disease Goals

December 19, 2017

(Reuters) – The early hope that stem cell therapy would make the paralyzed walk, the blind see and cure diabetes have given way to a long list of failures, highlighted by early stem cell champion Geron Corp abandoning the field in 2011.┬áBut two small companies, Athersys Inc and Mesoblast Ltd, are beginning final stage trials in hundreds of patients that they – along with loyal investors – say could change the course of devastating stroke and heart failure.┬áBoth have overcome major hurdles to manufacturing stem cell treatments on a large scale that are off-the-shelf products derived from healthy donor bone marrow and do not face immune system rejection issues.

Recommended Reading